SCHEMBL24726787

SCHEMBL24726787

COC(=O)CCCN/C=C/C[C@H]1C(=O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COc1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGFR P43088 11/20 0.67
PTGER3 P43115 10/20 0.67
MEN1 O00255 1/20 0.64
THRB P10828 1/20 0.64
KMT2A Q03164 1/20 0.64
MGLL Q99685 1/20 0.47
PTGER1 P34995 3/20 0.47
TBXA2R P21731 2/20 0.47
PTGER4 P35408 5/20 0.44
PTGIR P43119 4/20 0.44
PTGER2 P43116 3/20 0.44
NR1I2 O75469 1/20 0.44
ESR1 P03372 1/20 0.44
PGR P06401 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
OPRK1 P41145 1/20 0.44
PDE4D Q08499 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23640837 0.88 PTGFR (0.77) PTGFRPTGER3MEN1THRBKMT2A
SCHEMBL24340818 0.88 PTGFR (0.77) PTGFRPTGER3MEN1THRBKMT2A
SCHEMBL11891872 0.88 PTGFR (0.77) PTGFRPTGER3MEN1THRBKMT2A
SCHEMBL23353008 0.86 PTGFR (0.63) PTGFRPTGER3MEN1THRBKMT2A
Enprostil SCHEMBL10746961 0.83 PTGFR (0.64) PTGFRPTGER3MEN1THRBKMT2A
Enprostil SCHEMBL7107661 0.83 PTGFR (0.64) PTGFRPTGER3MEN1THRBKMT2A
Enprostil SCHEMBL10746954 0.83 PTGFR (0.64) PTGFRPTGER3MEN1THRBKMT2A
Enprostil SCHEMBL186877 0.83 PTGFR (0.64) PTGFRPTGER3MEN1THRBKMT2A
Enprostil SCHEMBL1650019 0.83 PTGFR (0.64) PTGFRPTGER3MEN1THRBKMT2A
SCHEMBL4303634 0.81 PTGFR (1.00) PTGFRPTGER3MEN1THRBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220281797-A1 KEY INTERMEDIATE FOR SYNTHESIS OF PROSTAGLANDIN COMPOUND AND PREPARATION METHOD THEREOF SHENZHEN CATALYS TECHNOLOGY CO., LTD (CN) 2022-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220281797-A1 KEY INTERMEDIATE FOR SYNTHESIS OF PROSTAGLANDIN COMPOUND AND PREPARATION METHOD THEREOF PTGES, PTGIS, PTGES2 PTGFR 8/4885PTGER3 19/4885MEN1 3136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.